Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine by Cheng, Liang et al.
OPEN
Molecular testing for BRAFmutations to inform
melanoma treatment decisions: a move toward
precision medicine
Liang Cheng1, Antonio Lopez-Beltran2,3, Francesco Massari4, Gregory T MacLennan5 and
Rodolfo Montironi6
1Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN,
USA; 2Unit of Anatomical Pathology, Faculty of Medicine, Cordoba University, Cordoba, Spain; 3The
Champalimaud Clinical Center, Lisbon, Portugal; 4Division of Oncology, S. Orsola-Malpighi Hospital,
Bologna, Italy; 5Department of Pathology, Case Western Reserve University and University Hospitals
Cleveland Medical Center, Cleveland, OH, USA and 6Institute of Pathological Anatomy and Histopathology,
School of Medicine, Polytechnic University of the Marche Region (Ancona), United Hospitals, Ancona, Italy
Approximately one-half of advanced (unresectable or metastatic) melanomas harbor a mutation in the BRAF
gene, with V600E being the most common mutation. Targeted therapy with BRAF and MEK inhibitors is
associated with significant long-term treatment benefit in patients with BRAF V600-mutated melanoma.
Therefore, molecular testing for BRAF mutations is a priority in determining the course of therapy. A literature
search was performed using MEDLINE/PubMed and scientific congress databases using the terms ‘BRAF,’
‘mutation,’ and ‘cancer/tumor.’ These results were filtered to include manuscripts that focused on diagnostic
tests for determining BRAF mutation status. Numerous BRAF testing methods were identified, including DNA-
based companion diagnostic tests and DNA- and protein-based laboratory-developed tests. Herein we review the
characteristics of each method and highlight the strengths and weaknesses that should be considered before
use and when interpreting results for each patient. Molecular profiling has shown that mutation load increases
with melanoma tumor progression and that unique patterns of genetic changes and evolutionary trajectories for
different melanoma subtypes can occur. Discordance in the BRAF mutational status between primary and
metastatic lesions, as well as intratumoral heterogeneity, is known to occur. Additionally, the development of
acquired resistance to combination BRAF and MEK inhibitor therapy is still a formidable obstacle. Therefore,
tumor heterogeneity and the development of acquired resistance have important implications for molecular
testing and ultimately the treatment of patients with advanced-stage melanoma. Overall, this information may
help community oncologists more accurately and effectively interpret results of diagnostic tests within the
context of recent data characterizing melanoma tumor progression.
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Melanoma represents a significant and increasing
public health burden and an ongoing area of unmet
need in oncology. Although melanoma accounts for
only 1% of diagnosed skin cancers, it is the cause of
most skin cancer-related deaths.1 In contrast to the
incidence of other common cancer types, the
incidence of melanoma is increasing.2 In the US,
87 110 new cases of melanoma and 9730 melanoma-
related deaths are estimated in 2017.2 Until recently,
patients with advanced melanoma had few effective
treatment options; historically, response rates to
conventional chemotherapy and immunomodula-
tion therapy (interleukin 2 or interferon gamma)
have been ~ 5–19%.3–6 New therapeutic options
include treatments targeted specifically to genetic
mutations in patients’ tumors as well as immune
checkpoint inhibitors.7–12
Many different methods for BRAF testing are
currently being used in the United States including
US Food and Drug Administration (FDA)-approved
companion diagnostic tests and various laboratory-
developed tests.13–15 Information on FDA-approved
tests for the detection of BRAF V600 mutations in
melanoma is available at http://www.fda.gov/compa
niondiagnostics.16 Each BRAF testing method has its
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own unique strengths, weaknesses, and challenges
that should be considered before using it to test a
patient’s tumor sample.13 This review will discuss
some of the currently available tests for determining
BRAF mutation status in patients with advanced
melanoma, focusing on considerations and
approaches for accurate and effective testing in the
community oncology setting.
BRAF-mutant metastatic melanoma: an
overview
A recent whole-genome sequencing study analyzing
mutation frequencies across several cancers identi-
fied melanoma as the most frequently mutated tumor
type;17 significant variation in the mutation profiles
for different types of melanoma (eg, cutaneous, acral)
has also been demonstrated by whole-genome
sequencing.18 The majority of melanomas have
mutations associated with the mitogen-activated
protein kinase (MAPK) pathway, an important signal
transduction pathway involved in cell growth,
proliferation, and survival.19 Oncogenic activation
of the MAPK pathway can occur via multiple
mechanisms, the most common of which in mela-
noma is constitutive activation of the BRAF kinase
via mutation, which occurs in ~40–60% of cases.
The second most common MAPK pathway aberra-
tion in melanoma is mutated NRAS, occurring in
~ 15–30% of cases.20–25
BRAF encodes a cytoplasmic serine–threonine
kinase. More than 97% of BRAF mutations are
located in codon 600 of the BRAF gene.13 The most
common mutation (in up to 90% of cases) is the
result of a transversion of T to A at nucleotide 1799
(T1799A), which results in a substitution of valine
(V) for glutamic acid (E) at position 600.26 Less
common are substitutions of V for lysine (V600K
(~8–20%)), arginine (V600R (1%)), leucine (V600M
(0.3%)), and aspartic acid (V600D (0.1%)).13,24 Non-
V600 mutations (eg, K601E, D594N) are also known
to occur in a low percentage of patients.13,27 Types
and frequencies of BRAF mutations are summarized
in Figure 1 and Table 1.26,27
BRAF-mutated melanoma tends to exhibit distinc-
tive clinical features and is characterized by more
aggressive biological behavior than BRAF wild-type
(WT) melanoma. Compared with patients with BRAF
WT melanoma, those with BRAF-mutated melanoma
are more often younger and have tumors with
superficial spreading or nodular histology and/or in
anatomical regions without chronic sun damage.24
Furthermore, BRAF-mutant tumors are more likely to
metastasize to the brain than BRAF WT tumors.25
BRAF-mutated melanoma has also been linked to
shorter overall survival in patients with stage IV
cancer than in those with BRAF WT disease.24,25,28
Given these features and the available effective
therapies, it is crucial to quickly determine whether
patients with melanoma have tumors harboring the
BRAF mutation in order to select the optimal
treatment.
The discovery that many melanomas harbor BRAF
mutations29 led to the development of vemurafenib
and dabrafenib, selective inhibitors of the BRAF
V600-mutated kinase, and trametinib and cobimeti-
nib, inhibitors of the downstream MEK kinase.
Combination therapy with BRAF and MEK inhibitors
(eg, dabrafenib plus trametinib, vemurafenib plus
cobimetinib) has resulted in dramatic improvements
in overall survival and progression-free survival
rates in patients with BRAF V600-mutant advanced
melanoma.30–35 Three-year landmark analysis
results have been presented from two randomized,
phase 3 studies evaluating dabrafenib plus
Figure 1 BRAF mutation types in melanoma. Estimated incidence
of BRAF mutation frequencies in patients with melanoma is
shown.26
Table 1 Incidence of common BRAF mutations based on the
COSMIC database26,27
BRAF mutation
Mutation at codon
600 of BRAF gene
Incidence in
BRAF-mutant
melanoma, %
Common BRAF mutations
V600E Valine → glutamic acid 84.6
V600K Valine → lysine 7.7
Other BRAF mutations
V600R Valine → arginine 1
V600M Valine → leucine 0.3
V600D Valine → aspartic acid 0.1
Non-V600 mutations
(eg, K601E, D594N)
— o1
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trametinib vs dabrafenib plus placebo (COMBI-d;
NCT01584648) or single-agent vemurafenib (COMBI-
v; NCT01597908) in patients with BRAF V600-
mutant advanced melanoma.36,37 The 3-year overall
survival and progression-free survival rates were 44
and 22%, respectively, with dabrafenib plus trame-
tinib vs 32% and 12%, respectively, with dabrafenib
plus placebo in COMBI-d. In COMBI-v, overall
survival and progression-free survival rates, respec-
tively, at 3 years were 45 and 24% with dabrafenib
plus trametinib vs 31 and 10% with vemurafenib.
The safety profile of long-term combination therapy
was similar to that in prior reports, with no
additional safety signals observed. Three-year land-
mark data are also available from the phase 3
coBRIM study (NCT01689519), which evaluated
cobimetinib plus vemurafenib vs placebo plus
vemurafenib in patients with advanced BRAF
V600-mutant melanoma; reported 3-year overall
survival rates were 37.4 and 31.5%, respectively.38
Currently, BRAF mutation status is the only
biomarker that predicts a therapeutic response in
advanced melanoma.39,40 Molecular testing for BRAF
mutations in patients with advanced melanoma has
become a standard for determining the course of
therapy, and testing is recommended by the current
National Comprehensive Cancer Network (NCCN)
and European Society for Medical Oncology guide-
lines for melanoma.40–42 However, it is important to
note that the NCCN Clinical Practice Guidelines in
Oncology (2017) do not recommend testing the
primary cutaneous melanoma for the BRAFmutation
unless required to guide systemic therapy.40 BRAF
inhibitors are approved only for use in patients with
a BRAF V600 mutation detected by an FDA-
approved test.43,44 Patients with BRAF WT tumors
may experience tumor promotion if treated with a
BRAF inhibitor due to the paradoxical activity of the
MAPK pathway in WT cells.43,44 Per NCCN guide-
lines, first-line systemic treatment options for
patients with metastatic or unresectable melanoma
include immunotherapy (ie, anti-programmed death
1 (PD-1) receptor monotherapy (pembrolizumab or
nivolumab) or nivolumab combined with the cyto-
toxic T-lymphocyte associated antigen 4 (CTLA4)-
targeted antibody ipilimumab), targeted therapy
(combination therapy with dabrafenib and trameti-
nib or vemurafenib and cobimetinib) for patients
with a BRAF V600 mutation, and enrollment in a
clinical trial.40 In patients with a BRAF mutation,
targeted therapy is preferred when an early response
is clinically needed; however, the optimal sequence
of BRAF inhibitors and immunotherapy is still under
investigation. Because combination therapy with
BRAF and MEK inhibitors has been shown to have
the potential for significant long-term treatment
benefit, identifying a patient’s BRAF mutation status
should be a priority for the clinician.
Evolution from benign to malignant
melanoma: primary and secondary
mutations
Although the BRAF V600 mutation is an oncogenic
driver mutation involved in cellular proliferation, it
is considered insufficient to induce melanoma in the
absence of other cytogenetic abnormalities. It has
been known for some time that BRAF V600 muta-
tions are frequently found in benign and dysplastic
melanocytic nevi, indicating that additional cellular
changes are needed for transformation.45 These
changes—including loss of tumor suppressors, acti-
vation of the TERT promoter, inactivation of genes
involved in DNA repair, or activation of other
protein kinases and signaling cascades46—in essence
release the ‘brakes,’ allowing cellular proliferation to
occur.46,47 Common genes in which loss-of-function
mutations can occur are CDKN2A, PTEN, and BAP1.
Mutation of CDKN2A, for example, removes a key
element of the p53 tumor suppressor pathway.48
Dysfunction of this pathway eliminates a mechanism
that would normally consign precancerous cells with
preexisting germline mutations or local, somatic
mutations to apoptosis or senescence. Thus, cells
that have a driver mutation combined with the loss
of a tumor suppressor are primed to undergo
transformation and develop into melanoma.
Determining genetic heterogeneity of
melanoma
Data have shown that the molecular profile of a
tumor changes over time due to various selection
pressures.46,47 Tumor heterogeneity in advanced-
stage melanoma has important implications for
molecular testing and thus treatment. Shain et al.
examined 37 primary melanocytic neoplasms and
their adjacent precursor lesions, ultimately micro-
dissecting and sequencing 150 distinct areas46
(Figure 2). Interestingly, tumors that lacked malig-
nant behavior harbored only BRAF V600E muta-
tions. The mutation load increased with progression,
and unique patterns of genetic changes, termed
‘evolutionary trajectories,’ for different melanoma
subtypes were observed. Intermediate lesions were
enriched for NRAS mutations and additional driver
mutations. Progression was marked by the appear-
ance of TERT promoter mutations and an increasing
burden of NRAS mutations in intermediate lesions.
This was followed by inactivation of CDKN2A or
mutations in SWI/SNF chromatin remodeling genes
in invasive melanomas and loss of PTEN and TP53
in advanced melanoma. In rare cases, lesions had
both BRAF V600E and NRAS mutations identified.
Although it is thought that BRAF and NRAS
mutations are mutually exclusive, this study by
Shain et al. and another recent study by Chiappetta
et al. showed that these mutations can both be
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present, most likely due to clonal heterogeneity
within the tumor.46,49
Researchers have evaluated the discordance in
BRAFmutation status between primary and matched
metastatic lesions in relation to the potential impli-
cations for therapeutic success and treatment
decision-making. Heinzerling et al. evaluated BRAF
mutation heterogeneity between tumor samples
isolated from the primary tumor and those from
metastases from patients with melanoma.50 In this
study, the tumors were not under the selection
pressure of a BRAF inhibitor because tumor samples
were collected prior to the availability of BRAF
inhibitor therapy. A total of 53 of the 187 patients
with melanoma had multiple tumor samples avail-
able for analysis. Ten of 53 patients (19%) had
discordant tumor samples that harbored both BRAF
WT and mutation-positive metastases. BRAF muta-
tions were as likely to first appear in metastases
derived from WT tumors as they were to be found in
the primary tumor that subsequently had WT
metastases. Additionally, similar to results reported
earlier by Shain et al,46 considerable intratumoral
heterogeneity was found using immunohistochem-
istry (IHC) staining for mutated BRAF, suggesting the
appearance of de novo BRAF mutations in the
metastases of some patients. The investigators
speculated that BRAF mutations may arise sponta-
neously in the secondary tumor from a BRAF WT
primary tumor. Alternatively, genetically heteroge-
neous metastatic tumors could derive from BRAF
mutation-positive or BRAF WT primary tumor cells,
leading to intrapatient discordance. It is also possible
that these results may have been a result of sampling
or the detection method used.50
Yancovitz et al. used mutation-specific real-time
polymerase chain reaction (RT-PCR) to examine
intra- and inter-tumoral heterogeneity of the BRAF
mutation.51 To determine intratumoral heterogene-
ity, laser microdissection of three to five sites from
nine primary melanomas was performed and
showed variability in the percentages of BRAF-
mutant cells across the tumor sites. Samples were
classified as unlikely to be heterogeneous (three
patients), likely to be heterogeneous (two patients),
or having marked heterogeneity (four patients). To
determine intertumoral heterogeneity, samples from
18 patients with matched primary and secondary
tumors and 19 patients with tumors from more than
one metastatic site were analyzed for concordance in
BRAFmutations. Discordance was observed between
primary and metastatic tumors in 8 of 18 patients
(44%) and between metastatic tumors in 5 of 19
patients (26%). The investigators suggested that
primary melanomas may contain mixed populations
of BRAF-mutant and BRAF WT cells, both able to
metastasize, and that resistance to targeted therapies
may be mediated by these genetically distinct tumor
Figure 2 Genomic evolution of melanoma. Genetic alterations accumulate during melanoma progression, from benign lesions that carry
the BRAF V600E mutation to intermediate lesions that have accumulated more genetic mutations to invasive melanoma that has acquired
pathogenic mutations that confer the ability to metastasize. As melanoma progresses, distinct evolutionary trajectories for different
melanoma subtypes develop.
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subclones.51 Data in support of this idea were
reported in a study by Colombino et al., who
analyzed 291 samples from 132 patients with
melanoma.20 Although BRAF mutations were
detected in 43% of primary tumors, the rate of BRAF
mutations in metastases was 5% greater (48%),
consistent with accumulation of de novo genetic
abnormalities as melanoma develops. Interestingly,
BRAF mutation concordance varied by metastasis
site: concordance with the primary tumor was
highest in lymph node and visceral metastases (93
and 96%) and lowest in skin and brain metastases
(75 and 80%).20
Bradish et al. evaluated the concordance in BRAF
mutational status between primary and matched
metastatic lesions collected from 25 patients with
metastatic melanoma.52 Six of these patients also had
multiple metastatic lesions available for testing.
None had received treatment with a BRAF inhibitor.
Using an RT-PCR kit able to detect five different
somatic BRAF V600 mutations—including the most
common V600E and less common V600K, V600D,
and V600R—intertumoral discordance was detected
in the tumors of four patients (16%). Of these four
patients, two had BRAF WT primary lesions with
BRAF V600-mutant metastatic lesions and the other
two had BRAF V600-mutant primary lesions with
BRAF WT metastatic lesions. Additionally, the
discordance rate was higher in patients with multi-
ple metastases (two of six (33%)) than in patients
with a single metastasis (two of 19 (11%)), indicating
that increasing the number of lesions tested increases
the likelihood of a discordant finding.
Together, these studies indicate that detection of a
negative BRAF mutation in the primary tumor may
not necessarily reflect the BRAF mutation status of
metastases. Therefore, clinicians should consider
repeat testing of the primary tumor and recent
metastatic site(s) to determine the BRAF mutation
status.52–54
Resistance to BRAF and MEK inhibitor
therapy
MAPK pathway inhibitors are an option for patients
with BRAF V600-mutant advanced melanoma.26,40,55
The introduction of BRAF inhibitor therapy was an
important step forward in the treatment of BRAF-
mutated melanoma. Yet up to one-half of patients
with BRAF-mutated tumors did not respond to
treatment in previous studies; in those who did
respond, acquired resistance generally developed at
a median of 6–7 months with single-agent BRAF
inhibitors.56,57 Combination treatment with BRAF
and MEK inhibitors has been shown to significantly
increase the proportion of patients with an objective
response while also significantly delaying the devel-
opment of acquired resistance.33,36,37,58,59 Therefore,
combination therapy (dabrafenib plus trametinib or
vemurafenib plus cobimetinib) is now considered a
standard of care in patients with BRAF-mutated
advanced melanoma.40
Mechanisms of de novo and acquired resistance to
BRAF inhibitor monotherapy were recently
described in a comprehensive review article by
Manzano et al 60 In vitro and in vivo models have
identified primary resistance mechanisms that drive
proliferation despite inhibition of BRAF V600 muta-
tions, including alterations in RAC1, loss of PTEN,
changes in cyclin-dependent kinase 4 and cyclin D1,
and stromal secretion of hepatocyte growth factor
activating c-MET.60 Several mechanisms of acquired
resistance have also been identified, including the
selection of subclonal populations that do not
express mutated BRAF (as previously discussed) or
populations that have alterations or mutations in
components of the MAPK (eg, NRAS mutations,
upregulation of tyrosine kinase receptors) or PI3K/
AKT pathways (eg, loss of PTEN) or changes in
downstream targets (eg, overexpression of transcrip-
tion factors). As with de novo resistance, these
mechanisms can drive proliferation.61
Although significant improvement in survival has
been achieved with combination BRAF and MEK
inhibition, de novo and acquired resistance continue
to be formidable obstacles.59 Patients with disease
progression on BRAF inhibitor therapy who subse-
quently received combination BRAF and MEK
inhibitor treatment had an overall response rate of
10–15%, indicating limited clinical benefit from
combination therapy once resistance had
developed.62,63 Long et al. evaluated resistance
mechanisms in 20 BRAF V600E-mutant tumor
samples from 10 patients with early resistance
(≤6 months of dabrafenib plus trametinib prior to
progression). MAPK pathway reactivation, indicat-
ing an ‘addiction’ to the MAPK pathway, was
observed in 9 of 10 tumors (90%). Resistance
mechanisms included BRAF amplification as well
as mutations in MEK1/2 and NRAS.64 In this and a
second study by Rizos et al, the rate of MAPK
pathway reactivation was higher than that pre-
viously observed in patients who progressed on a
BRAF inhibitor alone (50%).64,65
In vitro studies evaluating the pathophysiology of
acquired resistance to combination therapy have
shown that resistant melanoma cell lines exhibit a
much greater degree of drug addiction than cell lines
resistant to BRAF inhibitors alone.66 Similar to what
has been observed in tumors of patients who
progressed on a single BRAF inhibitor and were
then treated with BRAF and MEK inhibitors, BRAF
inhibitor-resistant cell lines demonstrated the ability
to rapidly adapt to combination therapy. This is
thought to be due to pre-existing resistance mechan-
isms. The researchers suggested that intermittent
drug dosing may be a strategy to delay the develop-
ment of acquired resistance, and further studies are
currently testing this hypothesis.66
A reduced ability to mount an antitumor immune
response has also been observed in patients who
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progressed on BRAF inhibitor monotherapy and
then received the combination of BRAF and MEK
inhibitor therapy.63 Chen et al evaluated 14 tumor
samples from a cohort of 23 patients refractory to
BRAF inhibitor therapy who were switched to
combination therapy. Prior to being treated with
combination therapy, the tumors showed a relatively
low number of tumor-infiltrating CD8-positive
T cells and limited expression of programmed
death-ligand 1 (CD274; previously named PD-L1).
When patients were switched to combination ther-
apy, an increase in immune cell infiltrate into the
tumor was observed in one of nine evaluable patients
who achieved stable disease.63
There is also great interest in combining BRAF and
MEK inhibitor therapy with immune checkpoint
inhibitor therapy.67 Preliminary animal models
evaluating the combination of MAPK pathway
inhibitors with checkpoint inhibitors suggest that
the combination may result in greater clinical benefit
than what can be achieved using either agent alone.
Working with tumor-bearing mice, Ebert et al
showed that MEK inhibition stimulated the infiltra-
tion of antigen-specific CD8-positive T cells and
prevented upregulation of programmed cell death
protein 1 (PDCD1). Furthermore, combining MEK
inhibition with anti-PDL1 therapy resulted in syner-
gistic antitumor activity.68 Another animal study
evaluated BRAF plus MEK inhibition combined with
anti-PDCD1 therapy and demonstrated superior
antitumor activity with the triple combination over
combined BRAF plus MEK or PDCD1 inhibition
alone.69 An ongoing clinical study (KEYNOTE-022;
NCT02130466) is evaluating dabrafenib plus
Figure 3 Processing of lesions for pathological analysis of BRAF V600 mutation. (a) The suspicious lesion is biopsied and prepared for
formalin-fixed, paraffin-embedded tissue. The tissue sample is immersed in 10% buffered formalin for 4–6 h, then immersed in a series of
increasingly concentrated ethanol to extract water. The final dehydration occurs in xylene, after which the tissue is immersed in a series of
increasingly concentrated molten paraffin. Finally, the sample is embedded in a block of paraffin suitable for serial sectioning. Serial
sectioning produces ‘ribbons’ of tissue sections that can be directly mounted onto slides, deparaffinized, and then stained. Every other
section is stained, typically with hematoxylin and eosin, to identify tumor margins while unstained alternate sections are used for
immunohistochemistry (IHC) or to obtain DNA for genetic analyses. In contrast to the process for surgical specimens, fine-needle aspirates
are taken and transferred directly from the syringe to a slide, where the material is smeared across its surface, air dried, and fixed. (b) IHC
reveals cellular expression of the BRAF kinase in BRAF mutation-positive (dark gray) cells in situ. (c) RT-PCR uses a fluorescent-labeled
target-specific probe allowing amplification of the target sequence and real-time quantification of PCR products. EtOH, ethyl alcohol.
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trametinib plus pembrolizumab in patients with
BRAF-mutant advanced melanoma.67 Another
ongoing study is evaluating sequencing of combina-
tion targeted therapy and checkpoint inhibitors
(EA6134; NCT02224781).
BRAF V600 mutation diagnostic tests
Obtaining and Processing Materials for BRAF Testing
After a preliminary diagnosis of stage III or IV
metastatic melanoma, the lesion(s) should be eval-
uated for BRAF mutational status.40 Cutaneous
lesions suspected of being melanoma are typically
resected with a wide margin, providing the entire
lesion and its margins for analysis. Radiologically
detected lesions within internal organs are sampled
by core-needle and/or fine-needle aspiration biopsy.
The postsurgical processing of surgical resections vs
fine-needle aspirates is slightly different. Biopsy
specimens are usually processed by formaldehyde
fixation and paraffin embedding in blocks for
subsequent IHC or DNA extraction for
sequencing70,71 (Figure 3).
Alternatively, a blood sample (‘liquid biopsy’) may
be assayed for circulating tumor DNA (ctDNA).72,73
ctDNA is composed of small fragments of nucleic
acids that are found in the circulation but are not
associated with any cell or cell fragment. Although
the mechanism by which ctDNA is released into the
blood is unclear, its abundance seems to reflect the
biological aggressiveness of the tumor.74–77 Despite
being an important innovation in cancer diagnostics,
ctDNA detection has limitations compared with a
tissue-based biopsy. Currently, ctDNA analysis is
less sensitive than tissue biopsy. Santiago-Walker
et al estimated the sensitivity of ctDNA testing for
BRAF V600E to be 76% relative to standard PCR
using a direct tumor biopsy. This was determined by
calculating the concordance in BRAF V600E-positive
mutation status between tissue biopsies and ctDNA
(N=661).78 Furthermore, because blood lacks anato-
mical specificity, the presence of BRAF-mutant DNA
in blood does not indicate the number of tumors or
the tumor origin. Additional diagnostic tests are still
required to identify the tumor site(s), which may add
to the overall expense, unlike conducting a standard
biopsy and mutational test.
Despite these limitations, ctDNA can provide
useful information for treatment monitoring. The
correlation between ctDNA abundance and disease
stage has been examined in patients with melanoma.
The quantity of BRAF V600E mutation-specific DNA
has been shown to be positively correlated to tumor
burden and disease stage.78–80 Accordingly, patients
with BRAF-positive ctDNA had significantly shorter
progression-free and overall survival than patients
without detectable BRAF-positive ctDNA.78 The
quantity of BRAF V600E-positive ctDNA was also
shown to be greater in patients with more metastatic
sites.81
BRAF Testing: Companion Diagnostic and Laboratory-
Developed Tests
BRAF genotype tests are classified as either compa-
nion diagnostic or laboratory developed, and US and
European regulatory agencies have issued guidelines
on their use. The European Medicines Agency
summary of product characteristics for vemurafenib
states that before starting treatment, a validated test
is required to identify BRAFmutation status but does
not specify which test should be used. It does state
that the cobas 4800 BRAF V600 Mutation Test
(Roche Molecular Systems, Inc) was used to identify
BRAF mutation-positive patients in the clinical trial
on which marketing approval was based.82 In the US,
companion diagnostic tests are often codeveloped
with a drug or drug class and are recommended and
approved by the FDA for informing the safe and
effective use of its corresponding therapeutic
product.83 Companion diagnostic tests undergo
rigorous testing and are reviewed by the FDA and
the US Centers for Medicare and Medicaid Services
to ensure analytical and clinical validity. In contrast,
laboratory-developed tests are typically designed,
developed, and used by a single institution, such as a
hospital or research laboratory.84,85 Unlike compa-
nion diagnostic tests, laboratory-developed tests are
not linked to a particular drug or drug class. Two
companion diagnostic tests are commercially avail-
able for detection of BRAFmutations: the cobas 4800
BRAF V600 Mutation Test for vemurafenib plus
cobimetinib and the THxID-BRAF kit (bioMérieux,
Inc) for dabrafenib plus trametinib.16 In addition,
laboratory-developed tests may be used to determine
a patient’s BRAF mutation status, provided that the
tests are reviewed and tested by the US Centers for
Medicare and Medicaid Services and used in a
Clinical Laboratory Improvement Amendments
(CLIA)-certified laboratory.84,86 In a recently pub-
lished survey of laboratories participating in the
College of American Pathologists proficiency testing
program for molecular analysis of BRAF mutations,
most evaluable reports (100 of 107 (94%)) included
only laboratory-developed procedures (the remain-
ing 7 included a companion diagnostic assay).87
Although the extent of regulatory oversight of
laboratory-developed tests has been minimal, the
FDA has developed more robust guidance as the
complexity of tests has increased. The FDA issued
draft guidance on the oversight of laboratory-
developed tests in 2014 and issued a discussion
paper in early 2017.84,88,89
Current and Developing Tests
Several BRAF mutation tests are currently in use;
they are classified as DNA based or antibody based.90
Modern Pathology (2018) 31, 24–38
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DNA-based tests include those that use PCR to
selectively amplify the mutant BRAF gene and others
that directly determine the nucleotide sequence of
the BRAF gene.26,90 Of note, PCR and other DNA-
based tests reveal the presence (or absence) of the
gene but do not indicate whether the gene is being
transcribed and translated into a protein.70,71
Currently, the only available antibody-based test
for mutant BRAF protein uses the monoclonal
antibody VE1 to detect expression in tumor samples
using IHC.26,90,91 This approach is effective in
identifying a qualitative change (ie, presence or
absence of the protein) but is less accurate in
quantitating changes in expression than other
antibody-based assays, such as the enzyme-linked
immunosorbent assay.92
Regardless of the technical approach used, every
test can be characterized by its sensitivity, specifi-
city, and limit of detection. Sensitivity is the ability
of the test to correctly identify BRAF mutations with
a low rate of false negatives. Specificity is the ability
of the test to correctly identify BRAF mutations with
a low rate of false positives. Limit of detection is the
threshold at which a signal (eg, DNA harboring the
BRAF mutation) can be distinguished from the
background (eg, BRAF WT DNA).93,94 Tests also
vary in terms of their selectivity.94,95 For example,
some tests can detect only the V600E mutation,
while others can detect V600E and other mutations,
such as V600K.14,15,91 This is important because
some agents (vemurafenib plus cobimetinib, trame-
tinib, and dabrafenib plus trametinib) have been
shown to be effective in patients with V600E/K
mutations.26,31–33
PCR DNA-Based Tests
The cobas 4800 BRAF V600 mutation test and the
THxID-BRAF kit both use RT-PCR to amplify and
detect the mutant DNA sequence in a tumor sample.
The major advantages of RT-PCR are faster perfor-
mance, better reproducibility, and lower cost com-
pared with traditional genomic sequencing methods.
The RT-PCR process is illustrated in Figure 3 and
includes an example of a data readout from an RT-
PCR assay. Briefly, the RT-PCR-based BRAF test uses
one primer set to detect the BRAF mutation and
another set to detect the WT sequence.14,45 Each
primer includes a distinct fluorophore and quencher.
The quencher prevents the excitation/emission of
light by the fluorophore as long as the primer is
unbound to DNA. As the DNA polymerase incorpo-
rates the primer into a new DNA strand, it cleaves
the quencher from the primer, freeing the fluoro-
phore to emit narrow-bandwidth light that can be
detected. As DNA is synthesized with each cycle, the
quantity of light increases relative to the abundance
of the DNA product, which is determined by the
number of cycles necessary for the intensity of
emitted light to cross an arbitrary threshold. TheTa
bl
e
2
C
om
p
ar
is
on
of
m
et
h
od
s
cu
rr
en
tl
y
u
se
d
fo
r
B
R
A
F
m
u
ta
ti
on
al
an
al
ys
is
T
H
xI
D
-B
R
A
F
ki
t
co
ba
s
48
00
B
R
A
F
V
60
0
m
u
ta
ti
on
te
st
S
an
ge
r
H
R
M
P
yr
os
eq
u
en
ci
n
g
IH
C
C
D
x
or
L
D
T
C
D
x
C
D
x
L
D
T
L
D
T
L
D
T
L
D
T
S
en
si
ti
vi
ty
,
%
4
96
fo
r
V
60
0E
;
4
92
fo
r
V
60
0K
~
97
fo
r
V
60
0E
;6
6–
70
fo
r
V
60
0K
92
–
98
98
–
10
0
4
98
85
–
10
0
S
p
ec
if
ic
it
y,
%
10
0
4
98
10
0
98
–
10
0
90
–
10
0
98
–
10
0
L
im
it
of
d
et
ec
ti
on
,%
5
fo
r
V
60
0E
,
V
60
0K
5–
7
fo
r
V
60
0E
;
4
35
fo
r
V
60
0K
6.
6
6.
6
5
5
M
u
ta
ti
on
s
d
et
ec
te
d
A
p
p
ro
ve
d
fo
r
V
60
0E
,
V
60
0K
A
p
p
ro
ve
d
fo
r
V
60
0E
on
ly
99
%
of
al
l
d
et
ec
ta
bl
e
m
u
ta
ti
on
s
99
%
of
al
l
d
et
ec
ta
bl
e
m
u
ta
ti
on
s
A
ss
ay
op
ti
m
iz
ed
fo
r
V
60
0
m
u
ta
ti
on
s
is
av
ai
la
bl
e
V
E
1
an
ti
bo
d
y
sp
ec
if
ic
fo
r
V
60
0E
S
am
p
le
T
u
m
or
-d
er
iv
ed
D
N
A
T
u
m
or
-d
er
iv
ed
D
N
A
T
u
m
or
-d
er
iv
ed
D
N
A
T
u
m
or
-d
er
iv
ed
D
N
A
T
u
m
or
-d
er
iv
ed
D
N
A
T
is
su
e
C
os
t
M
ed
iu
m
M
ed
iu
m
M
ed
iu
m
L
ow
H
ig
h
L
ow
A
bb
re
vi
at
io
n
s:
C
D
x,
co
m
p
an
io
n
d
ia
gn
os
ti
c;
H
R
M
,
h
ig
h
-r
es
ol
u
ti
on
m
el
t;
IH
C
,
im
m
u
n
oh
is
to
ch
em
is
tr
y;
L
D
T
,
la
bo
ra
to
ry
-d
ev
el
op
ed
te
st
.
Modern Pathology (2018) 31, 24–38
BRAF mutation testing in melanoma
L Cheng et al 31
relative abundance of BRAF V600E is determined by
comparing this threshold with the number of cycles
necessary to detect WT BRAF.
It is recommended that patients undergo an FDA-
approved test, such as the cobas 4800 BRAF V600
mutation test or THxID-BRAF kit, before starting
treatment with vemurafenib plus cobimetinib or
dabrafenib plus trametinib.14,15 The cobas 4800 test
has an analytical sensitivity of 95% for detecting the
V600E mutation.82 However, the test shows limited
cross-reactivity in detecting the V600D and K
mutations, and the package insert states that the test
does not detect non-V600E mutations reliably. The
recommended DNA input is 125 ng total, since the
test can detect the BRAF V600E mutation at ≥ 5%
using the standard input of 125 ng/25 μl.15 The
THxID-BRAF kit detects both V600E and K muta-
tions. The kit has been validated for DNA input of
10 ng/μl to 350 ng/μl.14 In contrast to the cobas 4800
test, the THxID test has a high degree of sensitivity
for both V600E and V600K (Table 2).
Although the RT-PCR-based cobas 4800 and
THxID assays are the companion diagnostic tests
for BRAF plus MEK inhibitor use, many treatment
centers use laboratory-developed tests based on
other DNA sequencing methods.87,90 The goal of
genomic sequencing in the context of BRAF testing is
to identify any one of the nucleic acid substitutions
associated with the mutant BRAF gene (Table 2). The
advantage of genomic sequencing is that it is not
specific for a certain mutation; therefore, any change
in the sequence may be identified. Three main
methods are currently being used: Sanger sequen-
cing, pyrosequencing, and high-resolution melt
analysis/real-time PCR.87,90,96 Next generation
sequencing platform is less frequently used in
clinical labs and is beyond the scope of this
review.90,97
Sanger sequencing. The Sanger sequencing
method, generally considered to be the gold stan-
dard, was developed in the 1970s and was the basis
for the method used by Venter et al in the Human
Genome Project to generate the first draft human
genome sequence.98 The Sanger method relies on
incorporation of deoxynucleotide triphosphates
(dNTPs; dATP, dCTP, dGTP, and dTTP) into a
complementary strand of DNA that exactly matches
a denatured target strand. The nucleotide sequence
is detected by chain termination, which results in
DNA strands of variable length. Chain termination
occurs due to the incorporation of 2′,3′-dideoxynu-
cleotide triphosphates (ddNTPs), which lack a 3′-OH
and thus cannot form a bond with the next dNTP.99
Reactions with each of four ddNTPs (ddATP, ddCTP,
ddGTP, and ddTTP) that are tagged with a radio-
active phosphate moiety or fluorophore are run in
parallel and resolved by electrophoresis. The length
of each DNA product indicates where the chain
terminated and which nucleotide was the last to be
incorporated. Advantages of Sanger sequencing
include reliability and availability and affordability
of the reagents; the primary disadvantage is its
relatively low sensitivity.
Jurkowska et al recently compared the reproduci-
bility of Sanger sequencing with that of the cobas
4800 test. Among 236 formalin-fixed, paraffin-
embedded tissue (FFPET) samples,100 Sanger
sequencing identified the V600E mutation in 60.9%
of samples and the cobas 4800 test identified it in
61%, with 95.2% agreement between the two tests.
Sanger sequencing also detected 10 non-V600E
mutations, while the cobas 4800 test detected 6.
Six cases were unamplifiable with the standard PCR/
sequencing method, five of which were identified as
V600E positive by the cobas 4800 test.
Lopez-Rios et al also compared Sanger sequencing
with the cobas 4800 test.101 The Sanger method
produced invalid results in 8 of 116 samples vs 0 of
232 with the cobas 4800 test. The positive percent
agreement with Sanger sequencing was 97.7%; the
negative percent agreement was 95.3%.
Qu et al performed a similar analysis and found
lower sensitivity for the cobas 4800 test than for the
Sanger method.102 In 275 FFPET samples, V600
mutations were identified in 35 and 43%, respec-
tively. Compared with Sanger sequencing, the cobas
4800 test exhibited 80.5% sensitivity and 99.4%
specificity. Of interest, 23 samples that were positive
with Sanger sequencing were discordant with the
cobas 4800 test. Based on these results, the authors
suggested that Sanger sequencing should be used to
test samples that are negative by the cobas 4800 test.
Pyrosequencing. In the early 2000s, multiple inno-
vations in sequencing methods were introduced.
One example is pyrosequencing. Like the Sanger
method, pyrosequencing relies on DNA synthesis,
but it detects the addition of new base pairs using an
enzymatic reaction that ultimately produces light.103
The process starts when target DNA is mixed with
one of four dNTPs. As the DNA polymerase
incorporates the complementary dNTP (A to T and
C to G) into the strand, a molecule of pyrophosphate
is released. The presence of sulfurylase in the
reaction converts pyrophosphate to adenosine tri-
phosphate, which interacts with luciferase, produ-
cing light. Each flash of light can be detected with a
charge coupled device camera, indicating the addi-
tion of specific dNTPs to the growing strand.104 As
with the Sanger method, a separate reaction is
required for each dNTP. However, four separate
reactions can be conducted simultaneously, greatly
speeding up the process.
Ihle et al used BRAF-specific pyrosequencing,
high-resolution melt analysis, multigene next-
generation sequencing, and IHC and compared these
techniques with the Sanger method for sensitivity
and specificity in detecting the BRAF mutation in
FFPET samples.13 Pyrosequencing was found to
have lower specificity than Sanger sequencing (90
vs 100%) but also a lower limit of detection. It
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detected mutant DNA in as few as 5% of copies
compared with 6.6% with Sanger sequencing and
7% with RT-PCR (Cobas 4800).
As with the Sanger method, multiple biological
steps are required for pyrosequencing. The process
takes 2–4 days to complete, the run itself is 10 h, and
additional time is required for bioinformatics analy-
sis. A key advantage of pyrosequencing is that it has
been adapted to a high-throughput platform, vastly
increasing the amount of generated data.103 The
disadvantages of pyrosequencing are high cost and
increased complexity and time. A high-throughput
pyrosequencing machine can cost 4$600 000, and
some reagents cost thousands of dollars.103 However,
because of the longer reads made possible by
pyrosequencing, the cost per base is lower than that
for Sanger sequencing. In addition, sequencing the
genome is unnecessary to determine the presence or
absence of the BRAF V600E mutation, and the
potential to detect multiple mutations with pyrose-
quencing has led to its increased use as a
diagnostic tool.
High-Resolution Melt Analysis/Real Time PCR
High-resolution melt is a sequencing technique that
incorporates aspects of PCR and sequencing by DNA
synthesis. High-resolution melt is a relatively simple
sequencing technique, as it is based on the principle
that double-stranded DNA denatures (ie, ‘melts’) at a
temperature that varies as a function of its G/C
content, length, and overall nucleotide sequence.105
The process normally begins with amplification of
the target DNA to nanogram quantities using PCR.105
Intercalating dyes (eg, SYBR Green, LC Green,
SYTO 9, and EvaGreen) are included in the reaction,
binding to double-stranded DNA but not single-
stranded DNA.106 Thus, fluorescence will initially be
high because the sample is composed solely of newly
synthesized, double-stranded DNA. While fluores-
cence is continually monitored, the PCR-amplified
sample is heated through a range of temperatures. As
the temperature gradually increases and the strand
begins to denature, the fluorescence slowly
decreases. Then, at a temperature characteristic of
the DNA strand’s G/C content, length, and overall
nucleotide sequence, the fluorescence falls rapidly,
indicating the complete separation of DNA into
single strands. The substitution of a single base can
lead to a 1 °C difference in the melting point, a
difference easily detected by the melting curve
shape. Data are usually presented as the derivative
of the melting curve, showing the change in
fluorescence over the change in temperature. The
sensitivity of the technique is directly related to
temperature control. The RapidCycler II (BioFire
Diagnostics, Inc (formerly known as Idaho Technol-
ogy, Inc)) and LightCycler 480 (Roche Diagnostics)
melts samples at 0.3 °C/sec, whereas the Rotor-Gene
6000 (Corbett Life Science, a QIAGEN company)
controls temperature at 0.017 °C/sec. The slower
melting time results in higher resolution and better
performance; however, the tradeoff is speed of data
acquisition.105 The RapidCycler can acquire data in
1–2min, whereas the Rotor-Gene device requires 20
min.105
The advantages of using high-resolution melt over
other techniques include low cost and increased
sensitivity and convenience. The PCR step and high-
resolution melt steps can occur in the same tube or
capillary, lowering the possibility of contamination
and reducing the likelihood of operator error. The
LightCycler 480 and RapidCycler II both provide
integrated PCR and high-resolution melt analysis in
one machine. Additionally, the technique is not
destructive, allowing additional analyses on the
same material. A disadvantage of high-resolution
melt is that it does not permit the direct identifica-
tion of the nucleotide sequence. However, from a
community clinician’s perspective, this may not
disqualify it as a technique since it screens for the
presence of the BRAF mutation, which is sufficient
for deciding whether to administer BRAF inhibitor
therapy.
A meta-analysis of 14 studies that included 1324
samples from patients with melanoma and other
cancers examined the sensitivity of high-resolution
melting in detecting BRAF mutation.106 Most of the
samples were obtained from FFPET, although some
were from fresh-frozen tissue. The pooled value of
the sensitivity of the high-resolution melting curve
analysis was high: 0.99 (range, 0.93–1.00). The
pooled specificity of the high-resolution melting
curve analysis was also 0.99 (range, 0.88–1.00).
Richter et al compared the BRAF mutational
testing accuracy of four techniques—high-resolution
melt, single-strand conformation analysis, Sanger
sequencing, and RT-PCR—in a blinded test across
two laboratories of 490 FFPET samples from
melanoma patients. They found 100% concordance
between the Sanger and high-resolution melt
techniques.96 Together, these results indicate a high
level of overall accuracy for high-resolution melt.
Protein Based Analysis (immunohistochemistry)
Although molecular testing is currently considered
to be the gold standard for the detection of BRAF
mutations, the monoclonal antibody VE1, developed
to specifically recognize a segment of the mutant
BRAF V600E protein, is emerging as a reliable
option.107,108 Since BRAF has a role in intracellular
signaling, BRAF staining is localized to the
cytoplasm.109 There are both advantages and dis-
advantages to IHC detection of mutant BRAF.96
Advantages include visualization of BRAF V600E-
mutant protein distribution at the single-cell level,
semiquantitative readout of protein abundance, and
high assay sensitivity and specificity. Because
FFPET samples are usually available as part of a
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regular biopsy, testing by IHC should be relatively
simple and inexpensive, and provide a fast turn-
around on results. The main disadvantages of IHC
include the possibility of false negatives due to high
heterogeneity or low abundance of BRAF V600E and
a lack of availability of antibodies for BRAF V600K
or other variants. In addition, because IHC recog-
nizes protein and not DNA, there may be discrepan-
cies between IHC and DNA-based test results.
Despite these drawbacks, reports have indicated that
the sensitivity and selectivity of the VE1 antibody
compare favorably with those of DNA-based tests.
Hugdahl et al used the VE1 antibody to assess the
frequency of the mutant BRAF V600E protein in 248
nodular melanomas and investigate its prognostic
value.28 They found BRAF V600E staining in 35% of
the cases. Tumors with BRAF V600E staining were
thicker and more likely to be ulcerated, and patients
with these lesions had reduced survival. Despite
these observations, BRAF V600E protein expression
independently predicted reduced survival, sepa-
rately, and distinctly from mitotic rate, presence of
ulceration, and tumor thickness. The concordance
between V600E staining and mutation status, as
assessed by PCR, was 88%. In a comparison of
Kaplan–Meier survival curves in patients grouped by
BRAF protein expression (n=248) and those
grouped by BRAF mutation status (n=191), the
researchers found that expression of the mutant
BRAF protein was a better prognostic indicator than
presence of the mutant BRAF gene. However,
caution should be taken when interpreting this
finding, since the analysis based on BRAF protein
expression included more patients than the analysis
based on BRAF gene presence and thus had more
statistical power.
Long et al compared the sensitivity and specificity
of VE1 immunostaining with those of a DNA-based
assay in 100 patients.110 VE1 immunostaining had a
sensitivity of 97% (37 of 38 paired samples yielded
identical results) and specificity of 98% (58 of 59) for
detecting the presence of the BRAF V600E mutation.
The authors noted that ‘…clinical use of the V600E
BRAF antibody should be a valuable supplement to
conventional mutation testing and allow V600E
mutant metastatic melanoma patients to be triaged
rapidly into appropriate treatment pathways.’
Further support for this conclusion was provided
by a study by Pearlstein et al, who compared VE1
immunostaining results with pyrosequencing results
in 76 patients with melanoma.111 A total of 27
patients (35%) had the V600E mutation, and another
nine had an alternate mutation (V600K, V600R, or
V600Q). Of these, there were five discordant cases in
which pyrosequencing reported the presence of the
V600E mutation but immunostaining was negative.
Further analysis of these discordant findings showed
that two of the five cases had a high percentage of
V600E allele frequency while two others demon-
strated a low allele frequency. The samples with a
low allele frequency suggest the possibility of tumor
heterogeneity. The final discordant case was reclas-
sified as it was found to have a BRAF V600K rather
than V600E mutation. Thus, the IHC test had a
sensitivity of 85% and specificity of 100% compared
with pyrosequencing.
Manfredi et al compared RT-PCR and high-
resolution melt analysis with IHC.112 Of 189 sam-
ples, 88 (47%) tested positive for BRAF V600E
mutation by IHC. The V600E-positive samples were
analyzed by genotyping of 74 samples, which
yielded interpretable results. Of these, only two
samples were not confirmed by both genotyping
methods. Of the 87 samples that were determined to
be BRAF V600E negative by IHC, 76 (87%) were
determined to be BRAF WT by molecular testing.
Ten of the remaining samples were determined to be
other BRAF V600 variants. Only one was determined
to be a true false-negative, as it was determined to be
BRAF V600E following molecular testing. Overall,
this analysis demonstrated that IHC testing with VE1
had high sensitivity (98.6%) and specificity (97.7%)
for IHC.112
Another challenge introduced by IHC staining is
the potential for subjective differences in interpreta-
tion between pathologists. A study by Eriksson et al
evaluated VE1-stained FFPE melanoma samples and
compared the reported interpretations with the
results of DNA sequencing.109 They asked three
observers to judge the staining intensity of samples
on a three-point semiquantitative scale. This method
resulted in a sensitivity of 96.7% and specificity of
94.5% for IHC with VE1. The level of agreement
between the observers was not reported. A 2014
study by Marin et al illustrated the potential
challenges associated with subjectivity introduced
with interpretation of IHC.113 In that study, seven
pathologists, two of whom had been previously
trained to interpret V600E staining, reviewed VE1
staining in samples from 67 patients. Concordance
between the seven pathologists was achieved only
79.1% of the time. This study emphasizes that VE1
staining has some diagnostic limitations and high-
lights the importance of training. Overall, the authors
of this study and others conclude that IHC can serve
as an important first step in determination of BRAF
V600E mutation status.96
Conclusions
The introduction of combination BRAF and MEK
inhibitor therapy has transformed treatment out-
comes in patients with advanced-stage BRAF-
mutated melanoma. Dramatic improvement in the
treatment of patients with advanced-stage melanoma
has occurred with the addition of checkpoint
inhibitors. The use of targeted therapy with immu-
notherapy, either in sequence or in combination, will
likely lead to further improvements in overall
survival.
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It is of paramount importance that a patient’s
BRAF mutational status is promptly and accurately
determined at the time of initial diagnosis, because it
is currently the only reliable predictive biomarker
that can influence the treatment of advanced
melanoma. VE1 immunostaining for the detection
of BRAF-mutated protein is a quick and inexpensive
test that can be combined with other melanoma
markers. However, since the only mutation that can
be detected with the VE1 antibody by IHC is the most
common V600E mutant, the presence or absence of
other mutations is not determined by this diagnostic
test; therefore, evaluation using DNA-based meth-
ods, such as the FDA-approved companion diagnos-
tic tests, is still needed. Newer technologies are
increasingly being used and refined (eg, evaluation
of ctDNA from ‘liquid biopsy’ samples) and will help
to address the shortcomings of tests that have been
used to date.72,73,76,77,81 Furthermore, the molecular
profile of a tumor has been shown to change over
time, and inter- and intratumoral heterogeneity can
make interpretation of test results challenging.
Therefore, it is recommended that repeat testing of
the putative primary tumor and recent metastatic
sites be performed. Much progress has been made in
tests for ctDNA, and this technology holds promise
as a tool for early on-treatment monitoring as well as
monitoring over time in the context of acquired
resistance. It is expected that in this age of precision
medicine, the future of BRAF biomarker testing will
see more techniques move out of the research space
and into the clinical practice setting.
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